Qiagen CFO Sees COVID Diagnostics Volatility Continuing In 2022
Executive Summary
Qiagen’s doubled-down focus on PCR technologies in late 2019 proved to be fortuitous, but future growth will come from many other drivers, says CFO Roland Sackers.
You may also be interested in...
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
Olympus Medical Follows The Patient Pathway In New Strategic Plan
Having divested non-medical imaging a year ago, Olympus Corp is putting its foot to the floor in refocusing on its medical portfolio. It has set global ambitions of strengthening its coverage of unmet needs and of playing a major role in reshaping health care delivery.
Cardio Industry Puts Weight Behind UK Call For National CVD Strategy
Better uptake of medtech in tackling cardiovascular disease can bring benefits across the entire pathway of care, say UK CVD companies, who are urging the government to improve levels of technology adoption.